Disitamab vedotin...has been granted conditional marketing approval by the National Medical Products Administration...of the People’s Republic of China for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least 2 types of systemic chemotherapy.